US03209R1032 - Common Stock
AMPHASTAR PHARMACEUTICALS IN
NASDAQ:AMPH (5/17/2024, 7:00:01 PM)
After market: 43.48 0 (0%)43.48
+0.74 (+1.73%)
Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. The company is headquartered in Rancho Cucamonga, California and currently employs 1,615 full-time employees. The company went IPO on 2014-06-25. The firm is focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. The company operates through two segments: finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Its portfolio also includes BAQSIMI (BAK-see-mee), which is used to treat very low blood sugar in people with diabetes ages 4 years and above.
AMPHASTAR PHARMACEUTICALS IN
11570 6th St
Rancho Cucamonga CALIFORNIA 91730
P: 19099809484
CEO: Jack Y. Zhang
Employees: 1615
Website: https://amphastar.com/
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the first quarter of 2...
Here you can normally see the latest stock twits on AMPH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: